Genome & Company (KOSDAQ:314130)
South Korea · Delayed Price · Currency is KRW 5,260.00
+810.00 (18.20%)
At close: Dec 5, 2025
Genome & Company Cash Flow Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 |
Net Income | -27,818 | -20,112 | -47,466 | -51,838 | -34,117 | -30,732 | Upgrade |
Depreciation & Amortization | 7,409 | 7,447 | 8,272 | 9,462 | 2,591 | 1,464 | Upgrade |
Loss (Gain) From Sale of Assets | 46.46 | 79.51 | 77.11 | -0.69 | 12.93 | 92.58 | Upgrade |
Asset Writedown & Restructuring Costs | 8,367 | 8,367 | 2,325 | - | - | - | Upgrade |
Loss (Gain) From Sale of Investments | 53.19 | -40.28 | -46.44 | - | - | - | Upgrade |
Stock-Based Compensation | 2,639 | 2,342 | 12,066 | 6,083 | 5,566 | 6,753 | Upgrade |
Provision & Write-off of Bad Debts | - | - | - | -12.92 | - | - | Upgrade |
Other Operating Activities | -4,918 | -8,964 | -4,648 | -3,864 | -1,658 | 4,592 | Upgrade |
Change in Accounts Receivable | -1,485 | -459.04 | 1,126 | -1,145 | 11.95 | - | Upgrade |
Change in Inventory | -170.2 | -1,898 | -1,694 | -886.4 | -154.36 | - | Upgrade |
Change in Accounts Payable | 223.24 | 88.24 | 132.77 | -139.79 | 14.8 | - | Upgrade |
Change in Other Net Operating Assets | -2,792 | -3,182 | -2,368 | -1,209 | 1,573 | -326.66 | Upgrade |
Operating Cash Flow | -18,445 | -16,331 | -32,224 | -43,550 | -26,159 | -18,157 | Upgrade |
Capital Expenditures | -1,153 | -3,970 | -18,853 | -6,849 | -2,875 | -1,504 | Upgrade |
Sale of Property, Plant & Equipment | -0 | - | - | 0.96 | 0.5 | 0.5 | Upgrade |
Cash Acquisitions | - | - | - | - | -26,721 | - | Upgrade |
Divestitures | - | - | - | - | - | 289.69 | Upgrade |
Sale (Purchase) of Intangibles | -148.72 | -216.34 | -189.09 | -427.29 | -504.78 | -325.02 | Upgrade |
Investment in Securities | 3,382 | 15,849 | 4,742 | 7,453 | -29,609 | 3,045 | Upgrade |
Other Investing Activities | 444.54 | -112.66 | -1,129 | -99.49 | -100.48 | 673.23 | Upgrade |
Investing Cash Flow | 2,525 | 11,551 | -15,430 | 77.52 | -59,810 | 2,179 | Upgrade |
Long-Term Debt Issued | - | 5,830 | 32,509 | - | - | - | Upgrade |
Long-Term Debt Repaid | - | -568.03 | -2,023 | -1,645 | -820.29 | -428.51 | Upgrade |
Net Debt Issued (Repaid) | -8,566 | 5,262 | 30,487 | -1,645 | -820.29 | -428.51 | Upgrade |
Issuance of Common Stock | 33.16 | 33.84 | 81.49 | 126.83 | 1,248 | 71,450 | Upgrade |
Other Financing Activities | 27,025 | -49.78 | - | 35.61 | 57.69 | 0 | Upgrade |
Financing Cash Flow | -9,580 | 5,246 | 30,568 | 78,550 | 17,617 | 98,633 | Upgrade |
Foreign Exchange Rate Adjustments | 4,115 | 8,727 | 1,226 | 1,089 | 453.3 | -646.07 | Upgrade |
Miscellaneous Cash Flow Adjustments | 0 | 0 | -0 | 0 | -0 | 0 | Upgrade |
Net Cash Flow | -21,385 | 9,192 | -15,860 | 36,167 | -67,898 | 82,010 | Upgrade |
Free Cash Flow | -19,599 | -20,301 | -51,077 | -50,399 | -29,034 | -19,662 | Upgrade |
Free Cash Flow Margin | -75.52% | -73.17% | -357.28% | -357.83% | -6434.20% | -13057.09% | Upgrade |
Free Cash Flow Per Share | -488.62 | -666.38 | -1808.70 | -1790.39 | -1080.03 | -1021.03 | Upgrade |
Cash Interest Paid | 593.73 | 587.12 | 310.78 | 170.8 | 52.71 | 48.13 | Upgrade |
Cash Income Tax Paid | - | 70.95 | 92.92 | 54.31 | 10.84 | 8.7 | Upgrade |
Levered Free Cash Flow | -17,282 | -17,433 | -31,442 | -35,323 | -17,129 | -76,734 | Upgrade |
Unlevered Free Cash Flow | -14,486 | -15,220 | -30,355 | -35,213 | -17,095 | -75,961 | Upgrade |
Change in Working Capital | -4,224 | -5,451 | -2,804 | -3,379 | 1,446 | -326.66 | Upgrade |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.